Jaguar Health Q3 2026 net loss narrows 40% year over year to $5.83 million
JAGX•Jaguar Health’s third-quarter 2026 net loss narrowed 40% year over year to $5.83 million, while total net revenue fell 24% to $2.34 million.
1. Quarterly results
Jaguar Health’s third-quarter 2026 net loss narrowed 40% year over year to $5.83 million. Total net revenue fell 24% to $2.34 million, and product revenue dropped 82% to $551,000.
2. Product licensing
The product revenue decline followed the licensing of Mytesi and Canalevia-CA1 to Future Pak. The agreement supports Jaguar Health’s strategic focus on developing crofelemer powder for rare diseases related to intestinal failure.




